FDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients ...

Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal disease in decade ...

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel ...

After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), ...

In CAH patients, the body is not able to produce cortisol, leading to serious health consequences. The absence of cortisol alters the normal feedback cycle of the hypothalamic-pituitary-adrenal ...

On Tuesday, Spruce Biosciences, Inc. (NASDAQ:SPRB) revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and ...

South San Franciso, California Thursday, December 12, 2024, 16:30 Hrs [IST] ...

Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. CAHmelia-204 ...

Wells Fargo analyst Steve Baxter maintained a Sell rating on Cardinal Health (CAH – Research Report) yesterday and set a price target of $101.00. The company’s shares closed yesterday at $123.51.

In a report released yesterday, Lisa Gill from J.P. Morgan maintained a Hold rating on Cardinal Health (CAH – Research Report), with a price target of $132.00. The company’s shares closed ...

CAHmelia-204 trial missed its primary goal of reducing daily glucocorticoid use in adults with CAH at 24 weeks. CAHptain-205 observed larger androstenedione reductions with higher BID doses of ...

"We are very grateful to all the patients, families, investigators, and the entire CAH community who supported the CAHmelia-204 and CAHptain-205 clinical trials. We garnered invaluable safety and ...